No Direct Interaction Between Rinvoq and Vitamin B12
Rinvoq (upadacitinib) does not have a documented interaction with vitamin B12, and no special B12 monitoring or supplementation is required solely because a patient is taking this medication. The FDA drug label for Rinvoq does not list any warnings, precautions, or interactions related to vitamin B12 1.
Key Clinical Points
No Evidence of B12 Interference
- The comprehensive safety analyses of upadacitinib across multiple conditions (rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, atopic dermatitis, and ankylosing spondylitis) do not report vitamin B12 deficiency as an adverse effect 2, 3
- Real-world effectiveness studies monitoring laboratory parameters in IBD patients on upadacitinib showed no clinically significant changes in biochemical parameters, with no mention of B12-related issues 4
Standard B12 Management Applies
If your patient requires B12 assessment or supplementation, follow standard guidelines independent of Rinvoq use:
When to consider B12 screening (per general medicine principles 5, 6):
- Inflammatory bowel disease (UC/CD) patients—relevant since Rinvoq is used for these conditions
- Patients on metformin >4 months or PPIs/H2 blockers >12 months
- Prior gastric/small bowel resection
- Age >75 years
- Vegans or strict vegetarians
B12 supplementation approach 5, 7, 8:
- Oral high-dose B12 (1-2 mg daily) is effective for most deficiency cases, including malabsorption
- Intramuscular therapy reserved for severe deficiency with neurologic symptoms or when rapid correction needed
- Treatment should be individualized based on symptom severity and cause of deficiency
Important Caveat for IBD Patients
Patients with ulcerative colitis or Crohn's disease treated with Rinvoq may have pre-existing risk for B12 deficiency due to their underlying disease (ileal involvement, prior resections, chronic inflammation), not due to the medication itself 6. Consider baseline B12 assessment in these populations as part of comprehensive IBD management.
Laboratory Monitoring on Rinvoq
The FDA label specifies monitoring requirements for Rinvoq 1:
- Absolute neutrophil count (interrupt if <1000 cells/mm³)
- Absolute lymphocyte count (interrupt if <500 cells/mm³)
- Hemoglobin (interrupt if <8 g/dL)
- Hepatic transaminases
Vitamin B12 is not part of the required monitoring panel for Rinvoq therapy.